IP Library Granted Patent US 10,272,165
Granted Patent B2
US 10,272,165 · App. 15/207,280 · Granted Apr 30, 2019

Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use

Inventors: John J. Rossi (Alta Loma, CA); Maggie Bobbin (Duarte, CA)
Assignee: CITY OF HOPE
A61K49/12A61K38/465A61K47/549A61K49/0054C12N15/111C12N15/115C12N15/1132A61K48/00C12N2310/14C12N2310/16C12N2310/3519C12N2320/32C12Y301/21004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,272,165
App. No.
15/207,280
Granted
Apr 30, 2019
Kind
B2
Abstract

An aptamer-mRNA conjugate is provided. The aptamer-mRNA conjugate may include an aptamer component that binds a membrane associated protein on a target cell and an mRNA component that is expressed by the target cell.

Claims (16)

1. An imaging method comprising:

administering an effective dose of one or more aptamer-mRNA conjugates to a subject, wherein each of the one or more aptamer-mRNA conjugates comprises:

an aptamer component that binds a membrane associated protein on a target cell; and

an mRNA molecule that encodes a diagnostic agent that is expressed by the target cell, wherein the aptamer component is conjugated to the mRNA molecule; and

exposing the subject to an imaging method.

2. The imaging method of claim 1 , wherein the diagnostic agent that is expressed by the target cell is a fluorescent protein or peptide.

3. The imaging method of claim 2 , wherein the fluorescent protein or peptide is green fluorescent protein (GFP), enhanced GFP (eGFP), red fluorescent protein, blue fluorescent protein, yellow fluorescent protein, cyan fluorescent protein, sapphire fluorescent protein, reef coral fluorescent protein, or a derivative thereof.

4. The imaging method of claim 1 , wherein the diagnostic agent that is expressed by the target cell is a luminescent protein or peptide.

5. The imaging method of claim 4 , wherein the luminescent protein or peptide is luciferase, aequorin, or a derivative thereof.

6. The imaging method of claim 1 , wherein the aptamer binds a target molecule on the surface of a cell and the mRNA molecule is expressed in the cell and visualized by the imaging method.

7. The imaging method of claim 1 , wherein the aptamer binds a target molecule on a pathogen and visualized by the imaging method.

8. The imaging method of claim 7 , wherein the pathogen is human immunodeficiency virus (HIV).

9. The imaging method of claim 1 , wherein the imaging method is positron emission tomography (PET), computer assisted tomography (CAT), single photon emission computerized tomography, x-ray, fluoroscopy, or magnetic resonance imaging (MRI).

10. The imaging method of claim 1 , wherein the aptamer-mRNA conjugates are delivered via dendrimers.

11. The imaging method of claim 1 , wherein the aptamer component and the mRNA molecule are conjugated covalently.

12. The imaging method of claim 1 , wherein the aptamer component and the mRNA molecule are conjugated non-covalently.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2016
From: BOBBIN, MAGGIE; ROSSI, JOHN J.
To: CITY OF HOPE
Reel/Frame 039372/0885 →
Continuity (4)
Division 14541639 · Nov 14, 2014
Division 13494880 · Jun 12, 2012
Provisional Application 61496027 · Jun 12, 2011
Related Publication 20170043040A1 · Feb 16, 2017